Advances in NeuroImmunoOncology:
Tyler E. Miller, David Gutmann, and Lukas Bunse addressed this topic in a plenary session at the AACR Special Conference on Brain Cancer. #AACRbrain26
@dhgutmann.bsky.social @lukasbunse.bsky.social

Advances in NeuroImmunoOncology:
Tyler E. Miller, David Gutmann, and Lukas Bunse will address this topic in a plenary session at the AACR Special Conference on Brain Cancer (March 23-25, 2026; Philadelphia). Learn more:
buff.ly/xqEJWTD
#AACRbrain26 @dhgutmann.bsky.social
@lukasbunse.bsky.social

Lautenschläger Prize for Young Scientists 2025 awarded to Lukas Bunse As a clinician scientist at the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University, neurologist Lukas Bunse is investigating how the body's own immune syste...

For his investigations how the body's own immune system can be supported in fighting brain tumors, Lukas Bunse (DKFZ & University Medical Centre Mannheim) has been awarded the Lautenschläger Prize for Young Scientists. 👏
@lukasbunse.bsky.social
t1p.de/4w2f5

The immunology of brain tumors The cellular and molecular determinants of the antigenicity of brain tumors and the immunosuppressive brain tumor microenvironment are reviewed.

The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/...

Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.

Thanks to the whole @acir-org.bsky.social team for this great and visible summary (as always!) of current advances in immuno-oncology!

Our CIMT coverage is out!
👉 Go to bit.ly/3SUQCOX to read a summary of select talks. #CIMT2025 Featured are: @ki.se‬  ‪@unileiden.bsky.social‬  ‪@ethz.ch‬  @niaidnews.bsky.social‬  ‪@dkfz.bsky.social‬  @lukasbunse.bsky.social‬  @biontech.bsky.social‬

Fantastic achievement! Congrats Annette! So well deserved!

Herzlichen Glückwunsch:
🏆️ Juniorprofessor Dr. Peter Andre @peterandre.bsky.social , #Wirtschaftspolitik, @safefrankfurt.bsky.social @goetheuni.bsky.social

🏆️ Dr. Lukas Bunse
@lukasbunse.bsky.social, #Neurologie, Universitätsmedizin Mannheim, Universität Mannheim 2/6

Huge congrats @lukasbunse.bsky.social, so well deserved, fantastic achievement.
@hlsalliance.bsky.social @cn-hd.bsky.social @neurooncologyhd.bsky.social @mctneuroscience.bsky.social @platten-lab.bsky.social

PTPRZ1 was upregulated in GBM samples and was associated with cell stemness (GSC score). [...] bit.ly/416M1wV   @lukasbunse.bsky.social

Congratulations to David for being a finalist for the YPIC #proteomics Fund!
We are happy to support his application at the Immunopeptidomics Platform HI-TRON and hope the fund will make this breakthrough project possible in collab with David from @lukasbunse.bsky.social lab at @dkfz.bsky.social

Thank you!😊

Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen
www.nature.com/articles/s41...
@lukasbunse.bsky.social @naturecomms.bsky.social

Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen - Nature Communications Vaccination in glioblastomas does lead to the emergence of tumour-antigen-specific T cells but T cell dysfunction, poor tumour infiltration and persistence hinder efficient tumour killing. Here author...

2/2 It was a great team effort led by fantastic Yu-Chan Chih @dkfz.bsky.social @mctneuroscience.bsky.social @neurooncologyhd.bsky.social @hlsalliance.bsky.social Read the full article here (open access):
www.nature.com/articles/s41...

Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen - Nature Communications Vaccination in glioblastomas does lead to the emergence of tumour-antigen-specific T cells but T cell dysfunction, poor tumour infiltration and persistence hinder efficient tumour killing. Here author...

1/2 Super excited to see this finally out @naturecomms.bsky.social ! We developed an off-the-shelf T cell receptor T cell therapy for patients with glioblastoma from a peptide vaccinated patient. Looking very much forward to its translation within DKTK supported by HI-TRON!

Great fun to write this perspective with @lukasbunse.bsky.social @platten-lab.bsky.social @dkfz-iic.bsky.social @dkfz.bsky.social on a highly interesting study by the Bardeesy Lab. This study provides additional mechanistic rationale to combine IDH inhibitors with T cell activating therapies.

Could not be any prouder. Stellar work, fantastic lecture - day to remember. Welcome to the faculty @lukasbunse.bsky.social.

Huge thanks to my fantastic mentor!